This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale at baseline
Timeframe: Baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after neoadjuvant chemotherapy treatment
Timeframe: through neoadjuvant chemotherapy treatment completion, average of 20 weeks from baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after surgery
Timeframe: through completion of surgery, average of 24 weeks from baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after radiation treatment
Timeframe: through radiation treatment completion, average of 30 weeks from baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after chemotherapy treatment
Timeframe: through chemotherapy treatment completion, average of 50 weeks from baseline
Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale after 24 weeks of endocrine treatment
Timeframe: through 24 weeks of endocrine treatment, average of 74 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) at baseline
Timeframe: baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after neoadjuvant chemotherapy treatment
Timeframe: through neoadjuvant chemotherapy treatment completion, average of 20 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after surgery
Timeframe: through completion of surgery, average of 24 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after radiation treatment
Timeframe: through radiation treatment completion, average of 30 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after chemotherapy treatment
Timeframe: through chemotherapy treatment completion, average of 50 weeks from baseline
Perceived Cognition measured by the Functional Assessment of Cancer Therapy - Cognitive (FACT-Cog) after 24 weeks of endocrine therapy treatment
Timeframe: through 24 weeks of endocrine treatment, average of 74 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) at baseline
Timeframe: baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after neoadjuvant chemotherapy treatment
Timeframe: through neoadjuvant chemotherapy treatment completion, average of 20 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after surgery
Timeframe: through completion of surgery, average of 24 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after radiation treatment
Timeframe: through radiation treatment completion, average of 30 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after chemotherapy treatment
Timeframe: through chemotherapy treatment completion, average of 50 weeks from baseline
Perceptual Fatigue as measured by the MD Anderson Brief Fatigue Inventory (BFI) after 24 weeks of endocrine treatment
Timeframe: through 24 weeks of endocrine treatment, average of 74 weeks from baseline